AMTB

AMTB

CAT N°: 25336
Price:

From 51.00 43.35

AMTB is an antagonist of transient receptor potential melastatin 8 (TRPM8).{37683} It inhibits calcium influx induced by the TRPM8 agonist icilin (Item No. 10137) with an IC50 value of 0.58 µM. AMTB (3 mg/kg) decreases the number of volume-induced bladder contractions in a rat model of noxious bladder distension. It also decreases the visceromotor reflex response to urinary bladder distension (ID50 = 2.42 mg/kg), indicating antinociceptive activity. AMTB inhibits the sodium channel (Nav) isoforms Nav1.1-1.8 (IC50s = 2-14.8 µM) and decreases viability of MDA-MB-231 and SK-BR-3 breast cancer cells (IC50s = ~23.7 and 17.3 µM, respectively) in a TRPM8-independent manner.{37684}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-(3-aminopropyl)-2-[(3-methylphenyl)methoxy]-N-(2-thienylmethyl)-benzamide, monohydrochloride
  • Correlated keywords
    • 926068-88-4 TRPM-8 anti-nociceptive MDAMB231 SKBR3 MDAMB-231 SKBR-3
  • Product Overview:
    AMTB is an antagonist of transient receptor potential melastatin 8 (TRPM8).{37683} It inhibits calcium influx induced by the TRPM8 agonist icilin (Item No. 10137) with an IC50 value of 0.58 µM. AMTB (3 mg/kg) decreases the number of volume-induced bladder contractions in a rat model of noxious bladder distension. It also decreases the visceromotor reflex response to urinary bladder distension (ID50 = 2.42 mg/kg), indicating antinociceptive activity. AMTB inhibits the sodium channel (Nav) isoforms Nav1.1-1.8 (IC50s = 2-14.8 µM) and decreases viability of MDA-MB-231 and SK-BR-3 breast cancer cells (IC50s = ~23.7 and 17.3 µM, respectively) in a TRPM8-independent manner.{37684}

We also advise you